Ananta Nanoo1, Alane Izu2, Nazir A Ismail3, Chikwe Ihekweazu1, Ibrahim Abubakar4, David Mametja5, Shabir A Madhi6. 1. Centre for Tuberculosis, National Institute for Communicable Diseases, Division of National Health Laboratory Service, Sandringham, Johannesburg, South Africa. 2. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. 3. Centre for Tuberculosis, National Institute for Communicable Diseases, Division of National Health Laboratory Service, Sandringham, Johannesburg, South Africa; Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Tshwane, South Africa. 4. Centre for Infectious Disease Epidemiology and MRC Clinical Trials Unit, University College London, London, UK; Public Health England, London, UK. 5. TB Cluster, National Department of Health, Tshwane, South Africa. 6. Centre for Tuberculosis, National Institute for Communicable Diseases, Division of National Health Laboratory Service, Sandringham, Johannesburg, South Africa; Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: shabirm@nicd.ac.za.
Abstract
BACKGROUND: South Africa has the highest incidence of tuberculosis in the world, largely resulting from a high population prevalence of HIV infection. We investigated the incidence of microbiologically confirmed pulmonary tuberculosis, and new cases of pulmonary tuberculosis registered for treatment, nationally and provincially in South Africa from 2004 to 2012, during which time there were changes in antiretroviral therapy (ART) coverage among individuals with HIV infection. METHODS: We identified cases of microbiologically confirmed pulmonary tuberculosis from 2004 to 2012 from the National Health Laboratory Service Corporate Data Warehouse. New cases registered for treatment were identified from National Department of Health electronic registries. A time series analysis, using autoregressive models, was undertaken on incidence of microbiologically confirmed pulmonary disease nationally and provincially; this trend was also examined relative to ART coverage of adults with HIV infection. FINDINGS: During the 9-year period, 3 523 371 cases of microbiologically confirmed pulmonary tuberculosis were recorded nationally. Annual incidence (per 100 000 population) increased from 650 (95% CI 648-652) in 2004 to 848 (845-850) in 2008, declining to 774 (771-776) by 2012 (9% decrease from 2008 to 2012). Incidence varied by age-group, sex, and province. There was an inverse association between incidence of microbiologically confirmed disease and ART coverage among HIV-infected individuals nationally and provincially. Trends in incidence of tuberculosis cases registered for treatment mirrored those of microbiologically confirmed cases nationally and provincially; however, incidence of microbiologically confirmed cases was consistently higher than cases registered for treatment nationally and in seven of nine provinces. INTERPRETATION: Since its peak in 2008, the incidence of microbiologically confirmed pulmonary tuberculosis in South Africa had declined by 2012; this decline is associated with an increase in ART coverage. Future integration of registries for microbiologically confirmed cases and new cases registered for treatment would improve the assessment of the burden of pulmonary tuberculosis in South Africa. FUNDING: National Institute for Communicable Diseases: Division of the National Health Laboratory Service, South Africa.
BACKGROUND: South Africa has the highest incidence of tuberculosis in the world, largely resulting from a high population prevalence of HIV infection. We investigated the incidence of microbiologically confirmed pulmonary tuberculosis, and new cases of pulmonary tuberculosis registered for treatment, nationally and provincially in South Africa from 2004 to 2012, during which time there were changes in antiretroviral therapy (ART) coverage among individuals with HIV infection. METHODS: We identified cases of microbiologically confirmed pulmonary tuberculosis from 2004 to 2012 from the National Health Laboratory Service Corporate Data Warehouse. New cases registered for treatment were identified from National Department of Health electronic registries. A time series analysis, using autoregressive models, was undertaken on incidence of microbiologically confirmed pulmonary disease nationally and provincially; this trend was also examined relative to ART coverage of adults with HIV infection. FINDINGS: During the 9-year period, 3 523 371 cases of microbiologically confirmed pulmonary tuberculosis were recorded nationally. Annual incidence (per 100 000 population) increased from 650 (95% CI 648-652) in 2004 to 848 (845-850) in 2008, declining to 774 (771-776) by 2012 (9% decrease from 2008 to 2012). Incidence varied by age-group, sex, and province. There was an inverse association between incidence of microbiologically confirmed disease and ART coverage among HIV-infected individuals nationally and provincially. Trends in incidence of tuberculosis cases registered for treatment mirrored those of microbiologically confirmed cases nationally and provincially; however, incidence of microbiologically confirmed cases was consistently higher than cases registered for treatment nationally and in seven of nine provinces. INTERPRETATION: Since its peak in 2008, the incidence of microbiologically confirmed pulmonary tuberculosis in South Africa had declined by 2012; this decline is associated with an increase in ART coverage. Future integration of registries for microbiologically confirmed cases and new cases registered for treatment would improve the assessment of the burden of pulmonary tuberculosis in South Africa. FUNDING: National Institute for Communicable Diseases: Division of the National Health Laboratory Service, South Africa.
Authors: I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh Journal: Int J Tuberc Lung Dis Date: 2018-06-01 Impact factor: 2.373
Authors: Anne F Luetkemeyer; Cynthia Firnhaber; Michelle A Kendall; Xingye Wu; Gerald H Mazurek; Debra A Benator; Roberto Arduino; Michel Fernandez; Elizabeth Guy; Pamela Johnson; Beverly Metchock; Fred Sattler; Edward Telzak; Yun F Wang; Marc Weiner; Susan Swindells; Ian M Sanne; Diane V Havlir; Beatriz Grinsztejn; David Alland Journal: Clin Infect Dis Date: 2016-02-02 Impact factor: 9.079
Authors: Grant Theron; Helen E Jenkins; Frank Cobelens; Ibrahim Abubakar; Aamir J Khan; Ted Cohen; David W Dowdy Journal: Lancet Date: 2015-10-26 Impact factor: 79.321
Authors: J C Hoogendoorn; L Ranoto; N Muditambi; J Railton; M Maswanganyi; H E Struthers; J A McIntyre; R P H Peters Journal: Epidemiol Infect Date: 2017-07-27 Impact factor: 4.434
Authors: K Rees; N Muditambi; M Maswanganyi; J Railton; J A McIntyre; H E Struthers; P B Fourie; R P H Peters Journal: Epidemiol Infect Date: 2017-12-06 Impact factor: 4.434